Activity of BMS-284756, a Novel Des-fluoro(6) Quinolone, Against Staphylococcus Aureus, Including Contributions of Mutations to Quinolone Resistance

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2002 Mar 19

PMID 11897603

Citations 8

Authors

D E Low

M Muller

C L Duncan

B M Willey

J C de Azavedo

A McGeer

B N Kreiswirth

S Pong-Porter

D J Bast

Affiliations

Soon will be listed here.

Abstract

The in vitro activity of BMS-284756 against 602 Staphylococcus aureus isolates, including 152 that were both methicillin and ciprofloxacin resistant (MIC > or = 4 microg/ml), was determined. For ciprofloxacin-susceptible and nonsusceptible isolates, the MICs at which 50% of organisms were inhibited were 0.015 and 2 microg/ml and the MICs at which 90% of organisms were inhibited were 0.03 and 4 microg/ml, respectively.

Citing Articles

In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.

Pucci M, Podos S, Thanassi J, Leggio M, Bradbury B, Deshpande M Antimicrob Agents Chemother. 2011; 55(6):2860-71.

PMID: 21464250 PMC: 3101440. DOI: 10.1128/AAC.01666-10.

Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.

Cheng J, Thanassi J, Thoma C, Bradbury B, Deshpande M, Pucci M Antimicrob Agents Chemother. 2007; 51(7):2445-53.

PMID: 17502409 PMC: 1913236. DOI: 10.1128/AAC.00158-07.

In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.

Pucci M, Cheng J, Podos S, Thoma C, Thanassi J, Buechter D Antimicrob Agents Chemother. 2007; 51(4):1259-67.

PMID: 17242152 PMC: 1855488. DOI: 10.1128/AAC.01315-06.

The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA....

Bhagwat S, Mundkur L, Gupte S, Patel M, Khorakiwala H Antimicrob Agents Chemother. 2006; 50(11):3568-79.

PMID: 16940059 PMC: 1635177. DOI: 10.1128/AAC.00641-06.

Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.

Campion J, Chung P, McNamara P, Titlow W, Evans M Antimicrob Agents Chemother. 2005; 49(6):2189-99.

PMID: 15917512 PMC: 1140504. DOI: 10.1128/AAC.49.6.2189-2199.2005.

References

Hooper D . Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001; 32 Suppl 1:S9-S15. DOI: 10.1086/319370. View

Kaatz G, Seo S, Ruble C . Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1993; 37(5):1086-94. PMC: 187905. DOI: 10.1128/AAC.37.5.1086. View

Discotto L, Lawrence L, Denbleyker K, Barrett J . Staphylococcus aureus mutants selected by BMS-284756. Antimicrob Agents Chemother. 2001; 45(11):3273-5. PMC: 90825. DOI: 10.1128/AAC.45.11.3273-3275.2001. View

Gootz T, Zaniewski R, Haskell S, Kaczmarek F, Maurice A . Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 1999; 43(8):1845-55. PMC: 89379. DOI: 10.1128/AAC.43.8.1845. View

Schmitz F, Jones M, Hofmann B, Hansen B, Scheuring S, Luckefahr M . Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother. 1998; 42(5):1249-52. PMC: 105791. DOI: 10.1128/AAC.42.5.1249. View